Coinsilium Group Ltd (AQSE:COIN, OTCQB:CINGF), the blockchain and open finance venture builder, today said it will participate in an online event called “The Metaverse, Play to Earn & BlackBots”.
The free to attend “showcase and educational session” will provide attendees with a basic understanding of these emerging apps, it said.
Don’t be fooled by the reported revenue numbers in Allergy Therapeutics PLC (AIM:AGY)’s half-year reports is the message from house broker finnCap.
The six-month trading update covering the second half of 2021 reflects the discontinuation of non-core products, ongoing COVID-19-related headwinds (principally in Germany and Italy), exchange-rate headwinds and product phasing issues, the broker explained, referring to a 10% reported year-on-year fall in revenues to £48.7mlm.
Ondine Biomedical Inc (AIM:OBI) has made a key senior appointment who will lead the commercialisation of the company’s breakthrough antimicrobial technology.
Charles Young is joining the group as its vice-president of sales and marketing in North America.
Caerus Mineral Resources PLC shares shot higher as it reported a high-grade gold intercept from drill hole testing at the Troulli-Kokkinapetra extension in Cyprus.
The hole returned a package width grade of 1.4g/t over 52.6m from the surface including one section of 4.97g/t over 11.55m.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said an ovarian cancer study has been hit by Coronavirus (COVID-19) delays, meaning it won’t now be completed until sometime in the first half of this year.
The problem is with a key external supplier, which has been unable to deliver certain reagents.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF), the gold, copper and silver producer, met output expectations in 2021 despite the challenges thrown up by the Coronavirus (COVID-19) pandemic.
The year saw the miner produce 64,610 gold equivalent ounces (GEOs), down from 67,249 ounces in 2020 but within the 64,000 to 72,000 ounces guidance range provided by the company.
Allergy Therapeutics PLC (AIM:AGY) said profits will be in line with market forecasts as it updated the market on trading and progress on its two key clinical trials.
Having made its investigational new drug application for its VLP Peanut allergy treatment, it now expects to start sharing data from its phase I study, named PROTECT, with the market in the third quarter of next year.
Mosman Oil and Gas Limited has postponed plans to consolidate its shares on a 100 into one basis after feedback from shareholders.